关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：301122 证券简称：采纳股份 公告编号：2025-100 采纳科技股份有限公司 1、公司拟购买的投资产品属短期低风险型产品，但金融市场受宏观经济影 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第十二次 会议、第三届监事会第十一次会议、2025 年第一次临时股东大会，分别审议通 过了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司 及全资子公司在确保不影响募集资金投资项目和公司正常经营，并有效控制风险 的前提下，使用额度不超过人民币 20,000 万元（含本数）的闲置募集资金（含 超募资金）和额度不超过人民币 80,000 万元（含本数）的自有资金进行现金管 理。使用期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内， 资金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具 体 由 公 司 财 务 部 负 责 组 织 实 施 。 具 体 内 容 详 见 公 司 在 巨 潮 ...

证券代码：301122 证券简称：采纳股份 公告编号：2025-097 采纳科技股份有限公司 关于部分募投项目结项并将节余募集资金 永久补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）于 2025 年 12 月 22 日召开第 三届董事会第十八次会议，审议通过了《关于部分募投项目结项并将节余募集资 金永久补充流动资金的议案》，同意公司募集资金投资项目"研发中心建设项目" 结项，并将节余募集资金（实际转出金额以转出当日银行结息余额为准）永久补 充流动资金，上述事项尚需提交公司股东会审议。现将具体情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意采纳科技股份有限公司首次公开发 行股票注册的批复》（证监许可[2021]3937 号），公司获准向社会公开发行人 民币普通股（A 股）股票 2,350.88 万股，每股面值人民币 1 元，发行价格为人 民币 50.31 元/股，募集资金总额为人民币 1,182,727,728.00 元，扣除各项发行 费用人民币 85,465,325.60 ...

证券代码：301122 证券简称：采纳股份 公告编号：2025-099 采纳科技股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 3、会议召开的合法、合规性：公司董事会召集本次股东会符合《中华人民 共和国公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》等有关法律法规、深圳证券交易所业务规则和《公司章程》的规定。 4、会议时间： （1）现场会议时间：2026 年 1 月 9 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 01 月 09 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为 2026 年 01 月 09 日 9:15 至 15:00 的任意时 间。 5、会议召开方式：现场投票+网络投票 重要提示： 采纳科技股份有限公司（以下简称"公司"）于 2025 年 12 月 22 日召开 ...

采纳科技股份有限公司 第三届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 采纳科技股份有限公司（以下简称"公司"）第三届董事会第十八次会议通 知于 2025 年 12 月 17 日以邮件、电话等方式向各位董事发出，会议于 2025 年 12 月 22 日以现场会议形式，在江苏省江阴市祝塘镇环西路 23 号采纳医疗办公 楼一楼会议室召开。本次会议由公司董事长陆军先生主持，会议应出席董事 9 人，实际出席董事 9 人，公司全体高级管理人员列席了会议。本次会议的召集、 召开及表决符合《中华人民共和国公司法》等有关法律、法规、规范性文件和《公 司章程》的规定。 二、董事会会议审议情况 1、审议通过《关于使用部分闲置募集资金和自有资金进行现金管理的议案》 在确保不影响募集资金投资项目建设和公司正常生产经营的前提下，拟使用 额度不超过人民币 2,000 万元闲置募集资金和额度不超过人民币 80,000 万元自 有资金进行现金管理，使用期限自股东会审议通过之日起 12 个月内有效。在上 述额度和期限内，资金可循环滚动使用 ...

南财智讯12月22日电，采纳股份公告，公司与薛利繁、苏州丰诚企业管理合伙企业（有限合伙）签署协 议，拟以2100万元收购江西丰临70%股权。本次交易完成后，公司将持有江西丰临70%股权。该事项不 构成关联交易，亦不构成重大资产重组。江西丰临是一家专注于注射穿刺类医疗器械产品的研发、生产 和销售的公司，主要产品包括输液类、注射类、采血类等医疗器械。 ...

Core Viewpoint - The company has approved the conclusion of the "Research and Development Center Construction Project" and plans to permanently supplement its working capital with the remaining funds from this project [1] Group 1: Project Conclusion - The company held its 18th meeting of the third board of directors on December 22, 2025, to review and approve the conclusion of the R&D center construction project [1] - The project has reached the predetermined usable status as of November 30, 2025 [1] Group 2: Financial Details - A total of 27.05 million yuan has been invested in the project, with approximately 20.95 million yuan remaining as surplus funds [1] - The final amount of surplus funds will be determined based on the bank account balance on the day of transfer [1] - The company plans to permanently allocate the surplus funds to its working capital after the transfer, and will subsequently cancel the corresponding fundraising special account [1]

Core Viewpoint - The company, Canar Medical, is experiencing a decline in stock price and revenue, while benefiting from the depreciation of the RMB due to its high overseas revenue proportion. Group 1: Company Overview - Canar Medical was established on July 23, 2004, and went public on January 26, 2022. The company is based in Jiangyin, Jiangsu Province, and specializes in the R&D, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables [7]. - The main revenue components of Canar Medical include syringes (45.17%), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7]. - As of November 28, the number of shareholders in Canar Medical is 8,801, a decrease of 2.05% from the previous period, with an average of 8,594 circulating shares per person, an increase of 2.09% [7]. Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Group 3: Market Activity - On December 19, Canar Medical's stock price fell by 0.28%, with a trading volume of 47.71 million yuan and a turnover rate of 2.26%, resulting in a total market capitalization of 3.428 billion yuan [1]. - The company has seen a net outflow of 4.69 million yuan from major investors today, ranking 115 out of 132 in its industry, and has experienced a reduction in major investor holdings for three consecutive days [4][5]. Group 4: Industry Context - Canar Medical began supplying IVF culture tube products to Thermo Fisher in 2018, indicating its involvement in the assisted reproductive technology and medical device sectors [2]. - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 90.61% of its total revenue [3].

Core Viewpoint - The company, Canar Medical, has shown a slight increase in stock price and is benefiting from the depreciation of the RMB, particularly in its overseas revenue which constitutes a significant portion of its business [1][3]. Group 1: Company Overview - Canar Medical was established on July 23, 2004, and went public on January 26, 2022. The company specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables [7]. - The main revenue components of Canar Medical include syringes (45.17%), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7]. - As of November 28, the number of shareholders in Canar Medical is 8,801, a decrease of 2.05% from the previous period, while the average circulating shares per person increased by 2.09% [7]. Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, representing a year-on-year decrease of 15.86%. The net profit attributable to the parent company was 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Group 3: Market Activity - On December 18, Canar Medical's stock price increased by 0.43%, with a trading volume of 46.28 million yuan and a turnover rate of 2.17%, resulting in a total market capitalization of 3.44 billion yuan [1]. - The company has been experiencing a net outflow of funds, with a net outflow of 1.05 million yuan on the day of the report, indicating a lack of strong market support [4][5]. Group 4: Technical Analysis - The average trading cost of Canar Medical's shares is 27.83 yuan, with the stock price currently near a support level of 27.75 yuan. There are indications of accumulation, but the strength of this accumulation is weak [6].

Core Viewpoint - The stock of Canan Technology Co., Ltd. experienced a decline of 3.28% on December 16, with a trading volume of 74.78 million yuan and a market capitalization of 3.419 billion yuan [1] Group 1: Company Overview - Canan Technology Co., Ltd. was established on July 23, 2004, and went public on January 26, 2022. The company is located in Jiangyin City, Jiangsu Province, and specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables [7] - The main revenue composition of the company includes: 45.17% from syringes, 45.01% from puncture needles, 5.49% from laboratory consumables, and 4.33% from other products [7] - As of November 28, the number of shareholders in Canan Technology was 8,801, a decrease of 2.05% from the previous period, while the average circulating shares per person increased by 2.09% to 8,594 shares [7] Group 2: Financial Performance - For the period from January to September 2025, Canan Technology reported a revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to the parent company of 8.25 million yuan, down 85.64% year-on-year [7] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8] Group 3: Market Position and Trends - Canan Medical began supplying IVF culture tube products to Thermo Fisher in 2018, indicating a strategic partnership in the assisted reproduction and medical device sectors [2] - The company benefits from a significant overseas revenue share of 90.61%, which is positively impacted by the depreciation of the Chinese yuan [3] - The average trading cost of the stock is 27.82 yuan, with the current price near a support level of 27.75 yuan, suggesting potential for a rebound if this support holds [6]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of CaiNa Co., Ltd., particularly its high PE ratio compared to industry averages [1][2] - As of December 12, CaiNa's closing price was 28.12 yuan, with a PE ratio of 883.31, significantly higher than the industry average of 50.65 [1][2] - The company's total market capitalization is 3.438 billion yuan, ranking it 124th in the medical device industry based on PE ratio [1][2] Group 2 - CaiNa's main business involves the research, production, and sales of injection and laboratory consumables, including various types of syringes and medical devices [1] - The latest financial report for Q3 2025 shows a revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit of 8.25 million yuan, down 85.64% [1] - The company's gross profit margin stands at 24.45%, indicating a significant decline in profitability [1]